ANDA Litigation Settlements

Fall 2012

GENERICally Speaking

Case Name

Drug

Patent
No(s).

Publicly Available Terms

Somaxon Pharma. Inc. v. Par Pharma. Inc., 11-0476 (D. Del.)

Somaxon Pharma. Inc. v. Mylan Inc., 11-0571 (D. Del.)

Silenor®(doxepin tablets)

7,915,307

6,211,229

Mylan will get exclusive right to start selling an authorized generic of Silenor in the U.S. on Jan. 1, 2020;

Mylan’s exclusivity is good for 180 days but may extended for up to 360 days;

Somaxon and Mylan also entered into a supply agreement;

In a separate agreement with Somaxon, Par will be able to start selling a generic version of Silenor 180 days after another generic version of Silenor is sold in the U.S. by a third party.

AstraZeneca Pharma LP v. Intellipharmaceutic Corp., 11-4498, 12-2855 (S.D.N.Y.)

Seroquel XR®(quetiapine fumerate extended-release tablets)

4,879,288

5,948,437

IPC shall not market its generic product until November 2016;

Patents-in-suit are valid and enforceable.

Pfizer Inc. v. Impax Labs., Inc., 08-2137 (D.N.J.)

Detrol®LA (tolterodine tartrate extended-release capsules)

5,382,600

6,630,162

6,770,295

N/A

Alza Corp. v. Impax Labs., Inc., 11-0395 (D. Del.)

Concerta®(methylphenidate hydrochloride extended-release tablets)

6,930,129

Impax may sell generic Concerta effective July 2014;

Impax’s settlement authorizes Teva to market Impax’s generic tablets.

Shire LLC v. Anchen Pharma., Inc., 10-0484 (D. Del.)

Intuniv®(guanfacine hydrochloride extended-release tablets)

6,287,599

6,811,794

5,854,290

Shire will receive royalties when TWI makes—and Anchen sells—generic Intuniv tablets effective July 1, 2016;

Anchen is TWI’s authorized distributor, but is also authorized to occasionally sell generic Intuniv tablets and pay Shire royalties.

Genzyme Corp. v. Impax Labs., Inc., 09-0653 (D. Md.)

Genzyme Corp. v. Impax Labs., Inc., 09-0846 (D. Md.)

Renagel®(doxepin tablets)

 

Renvela® (doxepin tablets)

5,667,775

Impax may sell certain dosages of generic Renagel tablets and generic Renvela liquid treatments effective Sept. 16, 2014;

Impax may sell other dosages of generic Renagel tablets effective Mar. 16, 2014.


Related Publications

August 29, 2019
Allergan Sales, LLC v. Sandoz, Inc
GENERICally Speaking Fall 2019
September 19, 2019
Amgen Inc. v. Amneal Pharms. LLC
GENERICally Speaking Fall 2019
Fall 2019
ANDA Approvals
GENERICally Speaking Fall 2019
Fall 2019
ANDA Litigation Settlements
GENERICally Speaking Fall 2019
July 17, 2019
Bausch Health Cos. v. Actavis Labs. FL
GENERICally Speaking Fall 2019
Back to Top